Neurocrine Biosciences (NBIX) market cap
Neurocrine Biosciences (NBIX) has a market cap of $16.79B. At the end of fiscal 2025 (December 31, 2025) its market cap was $14.54B. That is 2.7% higher than the $14.16B of fiscal 2024. Today's figure is 15.5% above the fiscal 2025 year-end. Figures as of 18 Nov 2026, 11:47 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Market cap today
- $16.79B
- Market cap, fiscal 2025
- $14.54B
- Change on fiscal 2024
- +2.7%
- Growth, 5 years
- +9.2% a year
- Growth, 10 years
- +11.8% a year
- Highest on record
- $14.54Bfiscal 2025
- Lowest on record
- $106.45Mfiscal 2009
- Fiscal years on record
- 172009–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Neurocrine Biosciences market cap, in more detail
Over the five fiscal years to 2025 the market cap grew at a compound 9.2% a year; over ten years the rate was 11.8% a year. Across the 17 fiscal year-ends on record (2009–2025), the highest was $14.54B in fiscal 2025 and the lowest $106.45M in fiscal 2009.
Market cap at each fiscal year-end
The last point is today's figure; the others are fiscal year-ends.
Neurocrine Biosciences market cap, year by year
| Fiscal year | Market cap | Change | Year ended | Share price at year-end | Diluted shares |
|---|---|---|---|---|---|
| Today | $16.79B | — | $165.92 | — | |
| 2025 | $14.54B | 2.7% up | $141.83 | 102.50M | |
| 2024 | $14.16B | 6.4% up | $136.50 | 103.70M | |
| 2023 | $13.31B | 12.7% up | $131.76 | 101.00M | |
| 2022 | $11.81B | 41.7% up | $119.44 | 98.90M | |
| 2021 | $8.34B | 11.1% down | $85.17 | 97.90M | |
| 2020 | $9.37B | 8.9% down | $95.85 | 97.80M | |
| 2019 | $10.29B | 51.0% up | $107.49 | 95.70M | |
| 2018 | $6.81B | 0.3% down | $71.41 | 95.40M | |
| 2017 | $6.83B | 103.7% up | $77.59 | 88.09M | |
| 2016 | $3.36B | 29.8% down | $38.70 | 86.71M | |
| 2015 | $4.78B | 186.9% up | $56.57 | 84.50M | |
| 2014 | $1.67B | 166.3% up | $22.34 | 74.58M | |
| 2013 | $625.68M | 24.9% up | $9.34 | 66.99M | |
| 2012 | $500.76M | 4.6% up | $7.48 | 66.95M | |
| 2011 | $478.95M | 18.7% up | $8.50 | 56.35M | |
| 2010 | $403.54M | 279.1% up | $7.64 | 52.82M | |
| 2009 | $106.45M | — | $2.72 | 39.14M |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Market cap is the share price multiplied by the number of shares: for past years this page multiplies the diluted share count in each annual report by the closing price for the month that fiscal year ended in, and today's figure comes from the live quote.
How to read it
It is what the stock market says the whole company is worth — a measure of size, not of whether the shares are cheap or dear.
Market cap at health care companies of similar size
| Company | Market cap |
|---|---|
| Revvity RVTY | $16.50B |
| Exelixis EXEL | $16.71B |
| Charles River Laboratories International CRL | $15.92B |
| Neurocrine Biosciences NBIX | $16.79B |
| Ascendis Pharma ASND | $17.79B |
| ICON ICLR | $14.61B |
Today's market value as the market data feed reports it, each in the currency its shares trade in.
Neurocrine Biosciences, figure by figure
- Neurocrine Biosciences revenue
- Neurocrine Biosciences earnings
- Neurocrine Biosciences earnings per share (EPS)
- Neurocrine Biosciences P/E ratio
- Neurocrine Biosciences P/S ratio
- Neurocrine Biosciences P/B ratio
- Neurocrine Biosciences free cash flow
- Neurocrine Biosciences operating margin
- Neurocrine Biosciences dividend
- Neurocrine Biosciences shares outstanding
- Neurocrine Biosciences total debt
- Neurocrine Biosciences cash on hand
- Neurocrine Biosciences total assets
- Neurocrine Biosciences return on equity (ROE)
- Neurocrine Biosciences return on invested capital (ROIC)
Neurocrine Biosciences (NBIX) overview: price, valuation and scorecardAll health care companies by market value
Neurocrine Biosciences market cap: questions and answers
What is Neurocrine Biosciences's market cap?
Neurocrine Biosciences (NBIX) has a market cap of $16.79B. At the end of fiscal 2025 (December 31, 2025) its market cap was $14.54B. That is 2.7% higher than the $14.16B of fiscal 2024.
What is the growth rate of Neurocrine Biosciences's market cap?
Over the five fiscal years to 2025 the market cap grew at a compound 9.2% a year; over ten years the rate was 11.8% a year.
What are the highest and lowest market cap figures on record for Neurocrine Biosciences?
Across the 17 fiscal year-ends on record (2009–2025), the highest was $14.54B in fiscal 2025 and the lowest $106.45M in fiscal 2009.
How is Neurocrine Biosciences's market cap calculated?
Market cap is the share price multiplied by the number of shares: for past years this page multiplies the diluted share count in each annual report by the closing price for the month that fiscal year ended in, and today's figure comes from the live quote. For Neurocrine Biosciences it is on record here for 17 fiscal years, 2009 to 2025.
Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.
Learn: market cap
All stocks guides →- What market capitalization is, and what it is not
Market capitalization is the share price multiplied by the number of shares outstanding: 1 billion shares at $50 is a $50 billion company. It measures the size the stock market puts on a company's equity today. It is not a sale price, it ignores debt and cash, and index providers often count only the freely traded part, the float.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Neurocrine Biosciences (NBIX) market cap”, data as of 18 November 2026. https://funkfolio.com/stock/NBIX/market-cap
Underlying data: the company's filings with the SEC and Yahoo Finance.